drugset / Trial / NCT03808558
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
Phase 2
Active not recruiting
18 enrolled
David E Gerber
Cancer Prevention Research Institute of Texas · collabGateway for Cancer Research · collabSagimet Biosciences Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective one-arm, two-stage phase 2 trial of TVB-2640 in KRAS mutant NSCLC patients. 13 patients will be treated with a minimum of 1 cycle of TVB-2640 therapy over 8 weeks.
Timeline
- Start
- 2019-09-11
- Primary completion
- 2025-04-03
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Denifanstat | Small molecule | 100 mg/m2 | Oral |
Indications
No indication recorded.